Terms: = Sarcomas AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Treatment
368 results:
1. FOXO3a deregulation in uterine smooth muscle tumors.
de Almeida TG; Ricci AR; Dos Anjos LG; Soares Junior JM; Maciel GAR; Baracat EC; Carvalho KC
Clinics (Sao Paulo); 2024; 79():100350. PubMed ID: 38636197
[TBL] [Abstract] [Full Text] [Related]
2. Bilateral diffuse metastases in advanced lung adenocarcinoma harboring egfr mutations was associated with a favorable prognosis to egfr-TKIs.
Gu Z; Huang P; Zhao J; Luo C; Liao L; Liu A; Huang L
Int J Cancer; 2024 Jun; 154(11):1979-1986. PubMed ID: 38353428
[TBL] [Abstract] [Full Text] [Related]
3. Novel KMT2B gene mutation in MUC4 positive low-grade fibromyxoid sarcoma.
Zhang L; Luo L; Liu C; Li Z
Diagn Pathol; 2024 Feb; 19(1):30. PubMed ID: 38347522
[TBL] [Abstract] [Full Text] [Related]
4. The role of high mobility group AT-hook 1 in viral infections: Implications for cancer pathogenesis.
Akade E; Jalilian S
Int J Biochem Cell Biol; 2024 Apr; 169():106532. PubMed ID: 38278412
[TBL] [Abstract] [Full Text] [Related]
5. Proteomics and genomics insights on malignant osteosarcoma.
Kathiresan N; Selvaraj C; Pandian S; Subbaraj GK; Alothaim AS; Safi SZ; Kulathaivel L
Adv Protein Chem Struct Biol; 2024; 138():275-300. PubMed ID: 38220428
[TBL] [Abstract] [Full Text] [Related]
6. Exploration of anti‑osteosarcoma activity of asiatic acid based on network pharmacology and
Pang H; Wu H; Zhan Z; Wu T; Xiang M; Wang Z; Song L; Wei B
Oncol Rep; 2024 Feb; 51(2):. PubMed ID: 38186298
[TBL] [Abstract] [Full Text] [Related]
7. Sotorasib with panitumumab in chemotherapy-refractory KRAS
Kuboki Y; Fakih M; Strickler J; Yaeger R; Masuishi T; Kim EJ; Bestvina CM; Kopetz S; Falchook GS; Langer C; Krauss J; Puri S; Cardona P; Chan E; Varrieur T; Mukundan L; Anderson A; Tran Q; Hong DS
Nat Med; 2024 Jan; 30(1):265-270. PubMed ID: 38177853
[TBL] [Abstract] [Full Text] [Related]
8. Efficacy of Pyrotinib With/Without Trastuzumab in treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer: Result From a Prospective Observational Study.
Zhou H; Lv M; Li W; Wang Y; Wu J; Liu Q; Liu T; Cui Y; Li Q
Clin Colorectal Cancer; 2024 Mar; 23(1):58-66. PubMed ID: 38177002
[TBL] [Abstract] [Full Text] [Related]
9. egfr-targeting peptide conjugated polymer-lipid hybrid nanoparticles for delivery of salinomycin to osteosarcoma.
Du L; Xu Y; Han B; Wang Y; Zeng Q; Shao M; Yu Z
J Cancer Res Ther; 2023 Dec; 19(6):1544-1551. PubMed ID: 38156920
[TBL] [Abstract] [Full Text] [Related]
10. Neoadjuvant Therapies Do Not Reduce Epidermal Growth Factor Receptor (egfr) Expression or egfr-Targeted Fluorescence in a Murine Model of Soft-Tissue sarcomas.
Streeter SS; Xu X; Hebert KA; Werth PM; Hoopes PJ; Jarvis LA; Pogue BW; Paulsen KD; Samkoe KS; Henderson ER
Mol Imaging Biol; 2024 Apr; 26(2):272-283. PubMed ID: 38151580
[TBL] [Abstract] [Full Text] [Related]
11. Exploration in the Mechanism of Ginsenoside Rg5 for the treatment of Osteosarcoma by Network Pharmacology and Molecular Docking.
Liu MY; Jiang DX; Zhao X; Zhang L; Zhang Y; Liu ZD; Liu RZ; Li HJ; Rong XY; Gao YZ
Orthop Surg; 2024 Feb; 16(2):462-470. PubMed ID: 38086608
[TBL] [Abstract] [Full Text] [Related]
12. The Future of HER2-Targeted treatment for Osteosarcoma: Lessons from the Negative Trastuzumab Deruxtecan Results.
Nakano K
Int J Mol Sci; 2023 Nov; 24(23):. PubMed ID: 38069146
[TBL] [Abstract] [Full Text] [Related]
13. [Clinical analysis of lung adenocarcinoma with epidermal growth factor receptor mutation transformed into sarcoma].
Zhu QQ; Du MZ; Wu WT; Guo LC; Huang JA; Shen D
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Jan; 47(1):24-30. PubMed ID: 38062690
[No Abstract] [Full Text] [Related]
14. Case report outcome of cetuximab treatment in a metastatic colorectal cancer patient with novel KRAS P34R.
Chen R; Yang D; Liu Y; Wang B; Xu H
Anticancer Drugs; 2024 Feb; 35(2):195-198. PubMed ID: 38018809
[TBL] [Abstract] [Full Text] [Related]
15. Detection of Novel Tyrosine Kinase Fusion Genes as Potential Therapeutic Targets in Bone and Soft Tissue sarcomas Using DNA/RNA-based Clinical Sequencing.
Hasegawa N; Hayashi T; Niizuma H; Kikuta K; Imanishi J; Endo M; Ikeuchi H; Sasa K; Sano K; Hirabayashi K; Takagi T; Ishijima M; Kato S; Kohsaka S; Saito T; Suehara Y
Clin Orthop Relat Res; 2024 Mar; 482(3):549-563. PubMed ID: 38014853
[TBL] [Abstract] [Full Text] [Related]
16. Liposarcoma of spermatic cord mimicking an inguinal hernia A case report and review of the literature.
Tinozzi FP; Calì B; Bertolami M; Rebba A; Morone G; Albertario S; Abbiati F; Osman N; Ruggiero R
Ann Ital Chir; 2023 Oct; 12():. PubMed ID: 37990578
[TBL] [Abstract] [Full Text] [Related]
17. Establishment and characterization of a recurrent malignant peripheral nerve sheath tumor cell line: RsNF.
Zhang X; Hu C; Li D; Liu S
Hum Cell; 2024 Jan; 37(1):345-355. PubMed ID: 37938540
[TBL] [Abstract] [Full Text] [Related]
18. Detecting acquired V-Raf murine sarcoma viral oncogene homolog B1 V600E mutation associated with osimertinib resistance in epidermal growth factor receptor-mutant lung adenocarcinoma: A case report.
Hagihara Y; Suetsugu T; Uto H; Kozono T; Masada Y; Satozono Y; Shinmura M; Koreeda Y; Mizuno K; Inoue H
Respir Investig; 2024 Jan; 62(1):13-15. PubMed ID: 37925883
[TBL] [Abstract] [Full Text] [Related]
19. Transcriptomic subtyping of malignant peripheral nerve sheath tumours highlights immune signatures, genomic profiles, patient survival and therapeutic targets.
Høland M; Berg KCG; Eilertsen IA; Bjerkehagen B; Kolberg M; Boye K; Lingjærde OC; Guren TK; Mandahl N; van den Berg E; Palmerini E; Smeland S; Picci P; Mertens F; Sveen A; Lothe RA
EBioMedicine; 2023 Nov; 97():104829. PubMed ID: 37837931
[TBL] [Abstract] [Full Text] [Related]
20. Network Pharmacology-Based Identification of Key Pharmacological Mechanism of Shen-qi-di-huang Decoction Acting on Uremia.
Zhang X; Chen XF; Chen WJ; Ding H; Zhang BX
Altern Ther Health Med; 2024 Jan; 30(1):44-50. PubMed ID: 37773677
[TBL] [Abstract] [Full Text] [Related]
[Next]
